Labcorp Receives Modern Healthcare’s 2025 Innovators Award

MEDevice Silicon Valley (formerly BioMed)

Swiss Biotech Insight Event

World CB & CDx Boston 2025

ASGCT 28th Annual Meeting

As you aim to hit your next milestone in cell and gene therapy development, Labcorp is here to collaborate and provide the critical insights you need to accelerate your progress. From discovery through clinical trials and long-term follow-up, we offer a comprehensive suite of testing solutions that span the entire development continuum.

Labcorp Publishes 2024 Corporate Responsibility Report

2025 ASCO® Annual Meeting

Expert answers for medical device safety testing questions: Using a comparative product as a control in the implant instead of HDPE or saline

Expert answers for medical device safety testing questions: Oxidized Surgical Tool Remediation

“I completed testing recently for cytotoxicity, intracutaneous irritation and Kligman maximization sensitization. My device is a limited-contact surgical tool primarily made of stainless steel. In the saline extracts, red/brown discoloration on the device and the same colored particulates in the extract were seen. I presume this is rust but want your input on what we can do next to determine the source of the rust and why it would happen if the device is made of stainless steel.”

Advancing the evaluation of amyloid pathology with pTau-217/Beta Amyloid 42 Ratio

The pathological hallmarks of Alzheimer’s disease (AD) are extracellular amyloid plaques consisting of aggregated beta amyloid (AB) peptides1 and intracellular neurofibrillary tangles containing abnormally phosphorylated tau (p-tau).2 Identification of these pathologies, particularly amyloid, is necessary for a clinical diagnosis of AD. Advancements in high-sensitivity immunoassay platforms have enabled blood-based biomarkers to be effective and accurate tools in the evaluation of individuals being evaluated for possible AD.